Sequential studies demonstrated a failure of targeted KRAS monotherapy to effectively treat individuals with PC and put aside this adjuvant plan from the PC clinic.92 More recently, the telomerase peptide vaccine was investigated as a combination with adjuvant chemotherapy. Here, KRAS is linked to pachyonychia congenita.